Trading
Please use a PC Browser to access Register-Tadawul
Akero Therapeutics To Present 96-Week Phase 2b SYMMETRY And HARMONY Data On Efruxifermin At 76th AASLD The Liver Meeting 2025
Share
Akero Therapeutics
AKRO
54.55
-0.15%